Skip to main content
Clinical Trials/NCT00829621
NCT00829621CompletedNot Applicable

Incisional Vacuum Assisted Closure (IVAC) Device and Its Effect on Implanted Bone Morphogenic Protein (BMP-2)

University of Missouri-Columbia1 site in 1 country20 target enrollmentStarted: December 1, 2008Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
20
Locations
1
Primary Endpoint
Presence of BMP-2 in Effluent Collected in IVAC Canister

Study Overview

Brief Summary

People who have been scheduled for surgery using Bone Morphogenic Protein (called BMP-2) and an incisional vacuum assisted closure device (called IVAC) will be asked to join this study.

The purpose of this study is to see if using the IVAC device removes BMP-2 from the wound. BMP-2 is a protein used by the body to increase bone healing, decrease the need for additional surgery, and reduce infection rates.

The IVAC is a device that involves a foam dressing secured with an adhesive drape to make an airtight seal over a surgical incision. Tubing runs from the foam dressing to a device that uses gentle suction to drain fluid out (like a vacuum). The IVAC stays on for 48-72 hours depending on amount of drainage. The IVAC by itself helps reduce wound swelling and complications (such as infection).

Detailed Description

It is hypothesized that the negative pressure associated with an IVAC is not sufficient to remove BMP-2 from a surgical wound.

BMP-2 is commonly used in open tibia fractures at the time of definitive wound closure, and these wounds are prone to increased swelling and wound complications. The recent observation that IVAC decreases wound edema and increases oxygenation has led to their use in such cases. Used in conjunction, it is entirely possible that the negative pressure exerted by the IVAC can remove BMP-2 from surgical site and therefore decreases the effectiveness of BMP-2. We seek to determine if BMP-2 is present in effluent from the IVAC. If in this study the hypothesis is found to be wrong, and BMP-2 is found within the IVAC effluent, we are prepared to proceed with a follow-up study to quantify the BMP-2 removed by the IVAC.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Subject is 18 years or older
  • •Subject has tibia fracture requiring treatment with BMP-2
  • •Subject to have an Incisional Vacuum Closure (IVAC) Device, placed on the skin directly over the BMP-2 implantation site
  • •Subject/guardian able to provide informed consent

Exclusion Criteria

  • •Subject is less than 18 years old
  • •Subject has a wound at fracture/surgical site that cannot be closed
  • •Subject/guardian unable to provide informed consent

Arms & Interventions

75 mmHg suction

Active Comparator

IVAC suction 75 mmHg

Intervention: 75 mmHg suction (Other)

125 mmHg suction

Experimental

IVAC suction 125 mmHg

Intervention: 125 mmHg (Other)

Outcomes

Primary Outcomes

Presence of BMP-2 in Effluent Collected in IVAC Canister

Time Frame: 12-hours, 24-hours, 36-hours, and 48-hours after IVAC application

Presence of BMP-2 in effluent collected in IVAC canister

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Brett Crist

Assistant Professor, Co-Director of Trauma Services, Co-Director Trauma Fellowship, Department of Orthopaedic Surgery

University of Missouri-Columbia

Study Sites (1)

Loading locations...

Similar Trials